Publication of List of Manufacturers Granted Licence for the Manufacture of Therapeutic Goods – 1 August 2022

Overview

The Therapeutic Goods Act 1989 was enacted to provide a legislative framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, ensuring their safety, quality, and efficacy. The Act was introduced to address the need for comprehensive regulation of therapeutic goods to protect public health by controlling the importation, supply, and manufacture of these goods within Australia. The enacting body was the Commonwealth Parliament, with the objective of safeguarding the health and safety of the Australian population by regulating the therapeutic goods market effectively. This legislation empowers the Therapeutic Goods Administration to oversee and enforce compliance with the standards and regulations stipulated within the Act.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity engaged in the manufacture, supply, or distribution of therapeutic goods within Australia, including the importation of such goods. This Act is a Commonwealth statute that applies nationally across all states and territories, regulating the quality, safety, efficacy, and performance of therapeutic goods, including medicines, medical devices, blood, and tissues. The Act ensures that therapeutic goods available in Australia meet necessary standards and are safe for consumers. The application of the Act is extensive, covering almost all aspects of therapeutic goods from pre-market approval to post-market surveillance. Notably, the Act includes provisions for the granting of licences to manufacturers, which are necessary for companies to legally produce therapeutic goods. The exclusions and exemptions from the Act are limited, generally focusing on certain low-risk goods and activities that are regulated under other legislation. Subordinate instruments and regulations may further define specific application details and compliance requirements, but these are generally consistent with the overarching objectives and provisions of the Therapeutic Goods Act 1989.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) governs the regulation of therapeutic goods in Australia, ensuring they meet safety, quality, and efficacy standards. Section 38 of the Act provides the Secretary with the authority to grant licences to manufacturers, allowing them to legally produce therapeutic goods. This section serves as the legislative basis for the publication of a list of manufacturers who have been granted these licences. The current publication (C2022G00713) includes specific licences issued to various companies, such as Botanical Resources Australia-Manufacturing Services Pty Ltd, Eurofins AMS Laboratories Pty Ltd, and others, each with a unique licence number and address details. The Act imposes several obligations on the entities granted manufacturing licences. These include adhering to Good Manufacturing Practice (GMP) standards, maintaining records of their manufacturing processes, and ensuring that the therapeutic goods they produce meet the required standards for safety, quality, and efficacy. Additionally, licence holders must submit applications for renewal or variation of their licences, as necessary, and respond to any requests for information or inspections from the Therapeutic Goods Administration (TGA). Compliance with these obligations is crucial for maintaining the licence and continuing operations. Failure to comply with the requirements of the Therapeutic Goods Act 1989 can result in serious consequences. The Act outlines various offences that can lead to criminal or civil penalties. For instance, manufacturing or supplying therapeutic goods that do not comply with the Act can result in criminal charges, with potential fines of up to $2.1 million for corporations and $420,000 for individuals, as specified in Section 32 of the Act. Additionally, the TGA can take action to suspend or cancel a manufacturing licence if it is found that the licence holder has breached the conditions of their licence, which can significantly impact the company's ability to operate in the market. Furthermore, there are also provisions for civil penalties, such as infringement notices, which can be issued for less serious breaches with fines up to $2,220 for individuals and $11,100 for corporations.